Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. is the subject of a cash tender offer by Harmony Row Acquisition Co., GlaxoSmithKline LLC and GSK plc to purchase all outstanding Class A and Class B shares for $124.00 per share. The Offer to Purchase and accompanying Letter of Transmittal dated June 24, 2026 set the terms and conditions, and the Schedule TO has been amended to add a press release by Ultimate Parent filed as Exhibit (a)(5)(K). The Offer Price is net to sellers in cash, subject to withholding taxes and the conditions in the Merger Agreement and Offer materials.
Nuvalent, Inc. recommends that holders accept the cash tender offer by Harmony Row Acquisition Co., an indirect acquisition vehicle of GSK plc, which offers $124.00 per Share in cash. The Offer will expire at one minute after 11:59 p.m. ET on July 14, 2026, subject to extension and customary conditions, including minimum tender and HSR clearance.
The Schedule 14D-9 describes that the Merger will occur under a merger agreement dated June 9, 2026, and that outstanding stock options, RSUs and PSUs will be cancelled for cash payments calculated using the Offer Price. The Board unanimously determined the Transactions are advisable and recommends tendering.
GSK plc, GlaxoSmithKline LLC and Harmony Row Acquisition Co. are offering to purchase all issued and outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share in cash, subject to the terms and conditions set forth in the Offer to Purchase and the Agreement and Plan of Merger. The Offer Price may be increased pursuant to the Merger Agreement.
As context, the Company reported 73,899,592 Class A Shares and 5,435,254 Class B Shares issued and outstanding as of June 17, 2026. The Schedule TO incorporates the Offer to Purchase, Letter of Transmittal and related exhibits, including the Merger Agreement dated June 9, 2026 and a Facility Agreement among financing parties.
Flynn James E reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. reported an updated insider position for entities affiliated with Deerfield Management Company, L.P., highlighting a new equity award tied to board service. On June 16, 2026, 3,444 restricted stock units (RSUs) were granted to director Cameron Wheeler, which are held for the benefit and at the direction of Deerfield Management.
Each RSU represents one share of Nuvalent Class A common stock and vests in full on the earlier of June 16, 2027 or the company’s next annual stockholder meeting, subject to Wheeler’s continued service. The filing also lists indirect Class A common stock holdings through several Deerfield funds, including 8,299,225 shares through Deerfield Healthcare Innovations Fund, L.P., 650,000 shares through Deerfield Partners, L.P., and 10,292 shares through Deerfield Management Company, L.P. The reporting persons disclaim beneficial ownership except to the extent of any indirect pecuniary interest.
Wheeler Cameron reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. reported that 3,444 shares of its Class A Common Stock were awarded in the form of restricted stock units to director Cameron Wheeler. The award was granted at no cash cost per share and brings the reported holding to 8,590 RSUs.
According to the disclosure, Wheeler is a partner in Deerfield Management Company, L.P., has no pecuniary interest in these securities, and holds them for the benefit and at the direction of Deerfield. The RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to continued service.
Srivastava Sapna reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Sapna Srivastava received an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. Each RSU represents the right to receive one share of Nuvalent Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the company’s next annual meeting of stockholders, subject to her continued service. Following this grant, she holds 8,590 shares of Class A Common Stock directly.
Squarer Ron reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Ron Squarer reported an equity award of Class A Common Stock in the form of restricted stock units. He received 3,444 RSUs, each convertible into one share of Class A Common Stock at no purchase price.
The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent’s next annual meeting of stockholders, as long as Squarer continues to provide service through that date. After this grant, his reported direct holdings total 6,281 shares.
Protopapas Anna reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Anna Protopapas reported an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase or sale.
Each RSU represents the right to receive one share of Nuvalent Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent's next annual meeting of stockholders, subject to her continued service through the vesting date. Following this grant, she holds 8,590 shares directly.
Oliger Christy J. reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Christy J. Oliger reported a compensation-related equity award of 3,444 shares of Class A Common Stock in the form of restricted stock units (RSUs). These RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to continued service. Following this grant, Oliger reports 7,415 shares of Class A Common Stock, including these RSUs, held directly.
Nuvalent, Inc. director Michael L. Meyers reported an equity grant of 3,444 shares of Class A Common Stock through restricted stock units (RSUs) at no cash cost. Each RSU converts into one share and vests in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to his continued service. Following this award, he holds 8,590 shares directly.